MCW Researcher Contributes to Paper Published on Combination Therapy of Dabrafenib/Trametinib for Tumors w/ BRAFV600E MutationsDr. Jong-In Park, Professor of Biochemistry, has contributed to a manuscript published in the Journal of Clinical Oncology about Combination Therapy of Dabrafenib/Trametinib for Tumors w/ BRAFV600E Mutations
BRAF/MEK inhibitor therapy has shown promising clinical activity in certain BRAF-mutated cancers, such as melanoma, non–small-cell lung cancer, and thyroid cancer. Early data suggested that responses to therapy may be histology dependent, because BRAF-mutated colorectal cancer demonstrated a relative resistance to therapy.
In many cancers, the incidence of BRAF mutations is low, and limited information exists regarding the sensitivity of other tumor types to BRAF/MEK inhibition. This study from the Arm H (EAY131-H) of the NCI-MATCH (Molecular Analysis for Therapy Choice) cancer trial sought to evaluate the efficacy of the BRAF/MEK inhibitors dabrafenib and trametinib in patients whose cancers have a BRAFV600 mutation after progression on standard therapy.
Dabrafenib and trametinib therapy resulted in responses in 38% of patients and showed a high rate of disease control. With more than 16 different tumor types represented, many patients seemed to benefit for several months. This study suggests that BRAF/MEK inhibition may be a viable treatment strategy across the majority of BRAFV600-mutated cancers. The NCI-MATCH is a “genotype to phenotype” phase II study and is the largest and most scientifically rigorous precision medicine cancer trial to date.
This trial consists of over 30 trial arms and is directed by Drs. Keith Flaherty (Harvard/MGH) and Alice Chen (NIH/NCI). Dr. Jong-In Park serves as the translational chair of EAY131-H and works with the two clinical chairs, Erin Macrae, MD (COHA) and April Salama, MD (Duke). EAY131-H determines therapeutic outcomes of the combination therapy in BRAFV600 cancer patients recruited regardless of the organs of tumor origin.